3 news items
Precipio to Report $15.2M for FY-2023 (unaudited) Revenues, an increase of 60% YoY
PRPO
13 Feb 24
. About Precipio Precipio is a healthcare biotechnology company focused on cancer diagnostics. Our mission is to address
Precipio And Cardinal Health Sign Distribution Agreement For Its HemeScreen Portfolio Of Molecular Assays For Cancer
CAH
PRPO
6 Feb 24
primarily the acute healthcare systems (hospital networks), as well as reference laboratories and physician owned laboratories
Precipio and Cardinal Health Sign Distribution Agreement for its HemeScreen® Portfolio of Molecular assays for Cancer
PRPO
6 Feb 24
assays to its customer base, which comprises primarily the acute healthcare systems (hospital networks), as well as reference laboratories and physician
- Prev
- 1
- Next